Switch theme
Sign up to access all valuation multiples
Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations.
1988
46
LTM Revenue $17.3M
LTM EBITDA $3.2M
$40.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biohit has a last 12-month revenue (LTM) of $17.3M and a last 12-month EBITDA of $3.2M.
In the most recent fiscal year, Biohit achieved revenue of $16.0M and an EBITDA of $3.3M.
Biohit expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biohit valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.3M | XXX | $16.0M | XXX | XXX | XXX |
| Gross Profit | $17.3M | XXX | $10.5M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $3.2M | XXX | $3.3M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $2.8M | XXX | $2.9M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | $2.9M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biohit's stock price is EUR 3 (or $3).
Biohit has current market cap of EUR 42.4M (or $47.6M), and EV of EUR 36.2M (or $40.7M).
See Biohit trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40.7M | $47.6M | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biohit has market cap of $47.6M and EV of $40.7M.
Biohit's trades at 2.5x EV/Revenue multiple, and 12.5x EV/EBITDA.
Equity research analysts estimate Biohit's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biohit's P/E ratio is not available.
See valuation multiples for Biohit and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $47.6M | XXX | $47.6M | XXX | XXX | XXX |
| EV (current) | $40.7M | XXX | $40.7M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 12.6x | XXX | 12.5x | XXX | XXX | XXX |
| EV/EBIT | 14.6x | XXX | 14.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 16.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 197.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiohit's last 12 month revenue growth is 16%
Biohit's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Biohit's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biohit's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biohit and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 21% | XXX | XXX | XXX |
| Rule of 40 | 32% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biohit acquired XXX companies to date.
Last acquisition by Biohit was XXXXXXXX, XXXXX XXXXX XXXXXX . Biohit acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biohit founded? | Biohit was founded in 1988. |
| Where is Biohit headquartered? | Biohit is headquartered in Finland. |
| How many employees does Biohit have? | As of today, Biohit has 46 employees. |
| Is Biohit publicy listed? | Yes, Biohit is a public company listed on HEL. |
| What is the stock symbol of Biohit? | Biohit trades under BIOBV ticker. |
| When did Biohit go public? | Biohit went public in 1999. |
| Who are competitors of Biohit? | Similar companies to Biohit include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Biohit? | Biohit's current market cap is $47.6M |
| What is the current revenue of Biohit? | Biohit's last 12 months revenue is $17.3M. |
| What is the current revenue growth of Biohit? | Biohit revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Biohit? | Current revenue multiple of Biohit is 2.3x. |
| Is Biohit profitable? | Yes, Biohit is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biohit? | Biohit's last 12 months EBITDA is $3.2M. |
| What is Biohit's EBITDA margin? | Biohit's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Biohit? | Current EBITDA multiple of Biohit is 12.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
